XOMA Receives $750,000 Milestone Payment From AVEO Pharmaceuticals

28-Jul-2010 - XOMA Ltd. announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc. The milestone payment resulted from AVEO's recent initiation of a Phase 2 clinical trial to evaluate its AV-299 antibody for the treatment of non-small cell lung cancer. AV-299 is a ...

XOMA Appoints Steven B. Engle President, Chief Executive Officer and Director

08-Aug-2007 - XOMA Ltd. announced that Steven B. Engle has been named president, chief executive officer and a member of the company's board of directors. Mr. Engle succeeds Jack Castello, the company's former president and chief executive officer, who announced his retirement plans earlier this year. Mr. ...

XOMA Announces Planned Retirement of Chief Executive Officer

28-Feb-2007 - Jack Castello, Chairman of the Board, President and Chief Executive Officer of XOMA Ltd. , announced his plans to retire. Mr. Castello, 70, chose to announce his retirement plans now to allow adequate time to find the best qualified individual to succeed him and make the management change as ...

XOMA and Affimed Sign Antibody Cross-License and Collaboration Agreement

05-Oct-2006 - XOMA Ltd. and Affimed Therapeutics AG have signed a cross-license and collaboration agreement for antibody-related technologies. Financial terms were not disclosed. The agreement provides XOMA with a license under Affimed's antibody library patents for antibody discovery purposes, as well as ...

Affitech and XOMA Sign Antibody Collaboration and Cross-License Agreement

01-Dec-2005 - Affitech AS and XOMA Ltd. announced that they have signed an antibody collaboration and crosslicense agreement for antibody-related technologies. Financial terms were not disclosed. Under the agreement, Affitech receives a license to use XOMA's bacterial cell expression (BCE) technology for ...

Chiron and XOMA announce initiation of phase I clinical trial fpr CHIR-12.12 in multiple myeloma

Second clinical trial evaluating oncology drug candidate begins

18-Oct-2005 - Chiron Corporation and XOMA Ltd. announced the initiation of a second clinical trial of CHIR-12.12, a novel, fully human, antagonist antibody that targets the CD40 antigen. The Phase I trial is for patients with multiple myeloma, a type of cancer that is associated with expression of the CD40 ...

XOMA Expands BCE Technology License with Crucell

07-Oct-2005 - XOMA Ltd. announced that it has expanded its existing non-exclusive, worldwide license to Crucell N.V. under XOMA's bacterial cell expression (BCE) technology to improve Crucell's position to perform phage display in the field of infectious disease with third party collaborators. Details of the ...

XOMA and Cubist Establish Strategic Antibody Manufacturing Relationship

22-Sep-2005 - XOMA Ltd. announced that it has signed a letter agreement with Cubist Pharmaceuticals, Inc. to develop new processes to manufacture a novel two-antibody biologic (HepeX-B(TM)) in quantities sufficient to conduct Phase III clinical trials. Specifically, the letter agreement calls for XOMA to ...

XOMA Licenses BCE Technology for Recombinant Protein Production to Wyeth

12-Sep-2005 - XOMA Ltd. announced that it has granted Wyeth a non-exclusive, worldwide license for XOMA's expression technology. Under the agreement, Wyeth receives a license to use XOMA's technology for the development and production of recombinant proteins. Details of the initial payment and future ...

XOMA Enters into License Agreement with Merck & Co., Inc.

21-Jun-2005 - XOMA Ltd. announced that it has granted Merck & Co., Inc. (Merck) a non-exclusive, worldwide license for XOMA's antibody-related intellectual property. Under the agreement, Merck receives a license to use XOMA's bacterial cell expression intellectual property for phage display with potential use ...